Compare BridgeBio Pharma Inc (BBIO) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Marsh & McLennan Companies, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.05B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 5.5× BridgeBio Pharma Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.08% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MRSH | |
|---|---|---|
Market Cap | $16.61B | $91.05B |
Sector | Health | Financials |
52-Week High | $90.17 | $211.21 |
52-Week Low | $47.29 | $157.32 |
Enterprise Value | $18.16B | $111.73B |
Dividend Yield | — | 2.08% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
